Phosphonoacetic acid had a significant antiviral effect when applied topically, both in liquid and ointment preparations, on superficial herpetic keratitis in rabbits and was equally as effective as idoxuridine. It was also effective in the treatment of idoxuridine-resistant herpetic keratitis. Phosphonoacetic acid was not effective in the treatment of experimental herpetic iritis when applied topically but was significantly effective when administered intravenously and subconjunctivally. No significant local or systemic toxicity was encountered.
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Phosphonoacetic acid (PAA) is a simple compound that is not an antimetabolite yet has been shown to inhibit herpes simplex virus (HSV) both in vitro and in vivo. A study by Shipkowitz et al. (10) in 1973 first showed that PPA suppressed HSV in tissue cultures, in herpetic dermatitis in mice, and in herpetic keratitis in rabbits. Recently, Gerstein et al. (3) showed that topical PAA was able to suppress clinical disease and virus replication in established herpetic keratitis in rabbits and was equivalent to idoxuridine (IDU) ointment. PAA appears to achieve its antiviral effect by inhibiting viral deoxyribonucleic acid (DNA) synthesis (8) . Preliminary results have indicated that PAA specifically inhibits the viral DNAdependent DNA polymerase (7) and does not inhibit normal cellular DNA polymerases. Since PAA is not an antimetabolite and has no significant effect on host ribonucleic acid or DNA synthesis, we designed a series of experiments to compare PAA against other antiviral agents and to test its effect against deeper ocular herpetic infections and IDU-resistant keratitis in rabbits.
MATERIALS AND METHODS
New Zealand white rabbits weighing 2 to 4 lb (about 9 to 18 kg) were used for the study. All Experimental herpetic iritis was produced by injecting 0.1 ml of a 1:5 dilution of the virus into the anterior chamber, using a 27-gauge needle on a tuberculin syringe. Before injection, the animals were sedated with intramuscular Thorazine and the corneas were topically anesthetized. The eyes were examined with a penlight and the iritis was graded on a scale of 0 to 4+. Zero indicated no iritis, mild iris injection was graded as 1+, moderate iris injection with edema was 2+, severe iris hyperemia and edema was 3+, and the presence of a hypopyon was graded as 4+. During the natural course of the iritis, maximum infection occurs on day 7 or 8 postinfection. Treatment of the iritis was started on the day 1 postinfection and continued daily for 8 days.
The water-soluble disodium salt of PAA was used throughout the study (Abbott Laboratories, North Chicago, Ill.). Topical preparations were either 5% solution in saline or 5% ointment in a petrolatum base. The intravenous preparation was in a concentration of 150 mg/ml dissolved in saline and given in a dosage of 150 mg/kg per day in a single daily dose. The subconjunctival preparation was in a concentration of 400 mg/ml in normal saline with a pH of 6.1 and was given as 0.25 ml (100 mg) injected beneath the conjunctiva superiorly once per day in each eye for 8 days.
The levels of severity of infection of the treatment groups were compared against one another each day by using the Kruskal-Wallis one-way analysis of variance (4) . If the test statistic was significant at the 5% level of significance, multiple comparisons were then made on all treatment groups by using Dunn's technique (2) . These tests were run at the 1% level of significance. RESULTS
The 5% PAA ointment was compared to the commercially available 0.5% Stoxil ointment (IDU) for effect on treating superficial keratitis. When both ointments were used four times per day there was no difference found between the healing promoted by the two agents, and both produced results significantly better than the control ointment (Table 1) on treatment days 4 and 5 when the controls were most severe.
When 5% PAA drops or 0.1% Stoxil drops were administered every 2 h around the clock to another group of animals, the severity of keratitis of both the PAA-and Stoxil-treated eyes was similar, and on day 5 both treatments were significantly better than the controls (Table 2) .
A simultaneous comparison of the 5% PAA drops and ointment was made, and both were compared with the Stoxil ointment. When all medications were given four times per day and evaluated on treatment days 4 and 5, all three treatment groups had significantly less severe keratitis than the controls. No significant difference was found between the PAA drops and ointment; both were equally effective (Table 3) .
In a trial against IDU-resistant herpes keratitis, 5% PAA drops administered six times a day was as effective as 1% trifluorothymidine drops on treatment days 4 and 5. The severity of keratitis of both treatment groups was significantly less than the controls (Table 4) . with topical 5% trifluorothymidine showed less severe iritis than the controls throughout most of the treatment period, with a significant difference noted on day 6 (Table 6 ). Subconjunctival injection of 100 mg of PAA per day was also effective for the treatment of this experimental iritis. By the 3rd treatment day, both the PAA-and trifluorothymidine-treated eyes had less severe iritis than the controls. A significant difference was found between the PAA-treated group and controls on days 4, 5, 6, and 7 (Table 7) .
DISCUSSION
The majority of antiviral agents known to ophthalmology, including IDU, adenine arabinoside, cytosine arabinoside, and trifluorothymidine, are antimetabolites. These drugs have been researched primarily for use in cancer chemotherapy. Because they are inhibitors of DNA synthesis they have also been found beneficial in viral chemotherapy. PAA (Fig. 1) , not an antimetabolite, appears now also to possess significant antiviral activity. When applied topically, either as an ointment or a drop, it causes a statistically significant suppression of experimental herpetic keratitis in rabbits. It appears to be as effective as IDU. Since the epithelial ulcer of herpetic keratitis is the direct cause of multiplying virus, this is the only parameter measured. Halting virus multiplication allows the ulcers to heal and provides a direct measure of antiviral efficacy. We therefore did not include other parameters that are not directly caused by virus multiplication.
Punctate epithelial toxicity, similar to that encountered with topical IDU, has been reported with the use of topical 5% PAA drops given eight times a day and has disappeared within 48 h after cessation of the medication (3). However, when given six times a day for 5 days to five uninfected rabbits, we found no (11) and intravenous adenine arabinoside (1) .
PAA, given subconjunctivally in an initial dosage of 150 mg/eye, caused necrosis of the surrounding conjunctiva and sclera. However, when the concentration was reduced from 600 to 400 mg/ml, delivering 100 mg/0.25 ml to each eye subconjunctivally, no conjunctival or scleral necrosis was noted. Disodium phosphonoacetate in a concentration of 400 mg/ml has a pH of 6.1, which was well tolerated by the tissues. There was essentially no difference in the amount of conjunctival inflammation noted between uninfected eyes receiving 100 mg of PAA or 0.25 ml of saline subconjunctivally. PAA given subconjunctivally significantly suppressed experimental herpetic iritis in rabbits.
Strains of HSV resistant to the antiviral effect of IDU are not uncommon (5) and will continue to be a problem as long as only one commercially available antiviral agent exists. These experiments show that IDU-resistant HSV keratitis can be successfully suppressed with PAA. The development of resistance to IDU does not appear to be accompanied by resistance to PAA. This is not uncommon, for it has also been shown that strains of HSV resistant to PAA are still amenable to treatment with adenine arabinoside (6) . This is consistent with the data showing that IDU resistance in HSV populations does not influence susceptibility to other antiviral agents (9) . Since IDU resistance is not an uncommon problem, it would be highly desirable to have alternative antiviral agents available for these patients.
